← All trials
NCT06548139
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2025
- First posted
- Aug 12, 2024
- Last posted
- Aug 12, 2024
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Changchun BCHT Biotechnology Co.Lead sponsor
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Yunnan University of Traditional Chinese MedicineCollaborator
- Anning City First People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.